据Acadia制药公司报告,其开发的精神分裂症辅助治疗药ACP-103在一项Ⅱ期临床试验中获得可喜的结果。ACP-103为一种选择性5HT2A反相激动剂,可与目前市场上的标准抗精神病药物联用,使这些药物能以较小的剂量达到同等疗效,并减少其副作用如增肥。它被认为是通过更有效地调节多巴胺 According to reports from Acadia Pharmaceuticals, ACP-103, an adjuvant schizophrenia developed by the company, has achieved promising results in a Phase II clinical trial. ACP-103, a selective 5HT2A inverse agonist, works with standard antipsychotic drugs on the market, enabling these drugs to achieve the same effect in smaller doses and reduce their side effects such as gaining weight. It is thought to regulate dopamine more effectively